Journal article
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
- Tsiogka A aDepartment of Dermatology, University Hospital of the Paracelsus Medical University bDepartment of Internal Medicine, Private Clinic Wehrle-Diakonissen, Salzburg, Austria cDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Jansky GL
- Bauer JW
- Koelblinger P
- 2017-09-01
Published in:
- Melanoma research. - 2017
Antineoplastic Agents, Immunological
Chemotherapy, Adjuvant
Diabetes Mellitus, Type 1
Humans
Ipilimumab
Male
Melanoma
Middle Aged
Neoplasm Recurrence, Local
Skin Neoplasms
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1097/CMR.0000000000000384
- PMID 28858175
- Persistent URL
- https://sonar.ch/global/documents/298412
Statistics
Document views: 22
File downloads: